Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical 25TFM-NBOMe
Research chemicalResearch chemicalPhenethylaminePsychedelicN-benzyl (NBOMe)5-HT2A agonist

25TFM-NBOMe

Also known as 2C-TFM-NBOMe · 25TFM

25TFM-NBOMe is the N-(2-methoxybenzyl) derivative of 2C-TFM (4-trifluoromethyl-2C). It is a potent NBOMe-class 5-HT2A agonist psychedelic, orally inactive and sub-milligram active, sharing the family's narrow margin, vasoconstriction and seizure risk.

01 Overview

25TFM-NBOMe carries a 4-trifluoromethyl group on the phenethylamine ring plus the NBOMe modification. It is a rare research chemical with no controlled human study.

Information is anecdotal. The trifluoromethyl group tends to confer high 5-HT2A affinity and metabolic stability, so the compound is expected to be potent and comparatively long-acting, with full NBOMe class toxicity.

02 Mechanism

Potent agonist at serotonin 5-HT2A receptors; the 4-CF3 ring group and N-2-methoxybenzyl substituent together produce high 5-HT2A affinity and potency.

03 Dosing

TierDoseRouteNotes
Threshold100–300 µgSublingualEstimated; potent.
Common300–1000 µgSublingualAnecdotal only.

04 Effects

EffectMagnitudeEvidence
Psychedelic effectsStrong visuals and cognitive alteration expected from a high-affinity NBOMe.8-12 hAnecdotal
StimulationBody load, tension and insomnia.markedAnecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Severe vasoconstrictionCold, painful extremities with hypertension and tachycardia.SevereCommonAnecdotal
Seizures and hyperthermiaOverdose can cause agitation, seizures, hyperthermia and rhabdomyolysis.Life-threateningUncommonAnecdotal

07 References

Trifluoromethyl phenethylamine hallucinogens and 5-HT2A activityACS Chemical Neuroscience, 2017
EMCDDA NBOMe overviewEMCDDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.